229 related articles for article (PubMed ID: 18842034)
1. Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.
Sehon CA; Wang GZ; Viet AQ; Goodman KB; Dowdell SE; Elkins PA; Semus SF; Evans C; Jolivette LJ; Kirkpatrick RB; Dul E; Khandekar SS; Yi T; Wright LL; Smith GK; Behm DJ; Bentley R; Doe CP; Hu E; Lee D
J Med Chem; 2008 Nov; 51(21):6631-4. PubMed ID: 18842034
[TBL] [Abstract][Full Text] [Related]
2. Rho kinase inhibitors as potential therapeutic agents for cardiovascular diseases.
Hu E; Lee D
Curr Opin Investig Drugs; 2003 Sep; 4(9):1065-75. PubMed ID: 14582450
[TBL] [Abstract][Full Text] [Related]
3. Vascular rho kinases and their potential therapeutic applications.
Budzyn K; Sobey CG
Curr Opin Drug Discov Devel; 2007 Sep; 10(5):590-6. PubMed ID: 17786858
[TBL] [Abstract][Full Text] [Related]
4. Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines.
Bosanac T; Hickey ER; Ginn J; Kashem M; Kerr S; Kugler S; Li X; Olague A; Schlyer S; Young ER
Bioorg Med Chem Lett; 2010 Jun; 20(12):3746-9. PubMed ID: 20471253
[TBL] [Abstract][Full Text] [Related]
5. Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors.
Goodman KB; Cui H; Dowdell SE; Gaitanopoulos DE; Ivy RL; Sehon CA; Stavenger RA; Wang GZ; Viet AQ; Xu W; Ye G; Semus SF; Evans C; Fries HE; Jolivette LJ; Kirkpatrick RB; Dul E; Khandekar SS; Yi T; Jung DK; Wright LL; Smith GK; Behm DJ; Bentley R; Doe CP; Hu E; Lee D
J Med Chem; 2007 Jan; 50(1):6-9. PubMed ID: 17201405
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.
Schirok H; Kast R; Figueroa-Pérez S; Bennabi S; Gnoth MJ; Feurer A; Heckroth H; Thutewohl M; Paulsen H; Knorr A; Hütter J; Lobell M; Münter K; Geiss V; Ehmke H; Lang D; Radtke M; Mittendorf J; Stasch JP
ChemMedChem; 2008 Dec; 3(12):1893-904. PubMed ID: 18973168
[TBL] [Abstract][Full Text] [Related]
7. Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 2, optimization for blood pressure reduction in spontaneously hypertensive rats.
Ginn JD; Bosanac T; Chen R; Cywin C; Hickey E; Kashem M; Kerr S; Kugler S; Li X; Prokopowicz A; Schlyer S; Smith JD; Turner MR; Wu F; Young ER
Bioorg Med Chem Lett; 2010 Sep; 20(17):5153-6. PubMed ID: 20678931
[TBL] [Abstract][Full Text] [Related]
8. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
[TBL] [Abstract][Full Text] [Related]
9. Triazine and pyrimidine based ROCK inhibitors with efficacy in spontaneous hypertensive rat model.
Ho KK; Beasley JR; Belanger L; Black D; Chan JH; Dunn D; Hu B; Klon A; Kultgen SG; Ohlmeyer M; Parlato SM; Ray PC; Pham Q; Rong Y; Roughton AL; Walker TL; Wright J; Xu K; Xu Y; Zhang L; Webb M
Bioorg Med Chem Lett; 2009 Nov; 19(21):6027-31. PubMed ID: 19800787
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
[TBL] [Abstract][Full Text] [Related]
11. Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.
Wang T; Lamb ML; Scott DA; Wang H; Block MH; Lyne PD; Lee JW; Davies AM; Zhang HJ; Zhu Y; Gu F; Han Y; Wang B; Mohr PJ; Kaus RJ; Josey JA; Hoffmann E; Thress K; Macintyre T; Wang H; Omer CA; Yu D
J Med Chem; 2008 Aug; 51(15):4672-84. PubMed ID: 18646745
[TBL] [Abstract][Full Text] [Related]
12. Development of Rho-kinase inhibitors for cardiovascular medicine.
Shimokawa H; Rashid M
Trends Pharmacol Sci; 2007 Jun; 28(6):296-302. PubMed ID: 17482681
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of Rho kinase inhibitors (II).
Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Ohashi H; Sato M; Sugiyama T; Fukushima K; Iijima H
Bioorg Med Chem; 2007 Jan; 15(1):350-64. PubMed ID: 17046269
[TBL] [Abstract][Full Text] [Related]
14. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of potential Rho-kinase inhibitors based on the chemistry of an original heterocycle: 4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one.
Letellier MA; Guillard J; Caignard DH; Ferry G; Boutin JA; Viaud-Massuard MC
Eur J Med Chem; 2008 Aug; 43(8):1730-6. PubMed ID: 18164518
[TBL] [Abstract][Full Text] [Related]
16. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
Zhu GD; Gandhi VB; Gong J; Thomas S; Woods KW; Song X; Li T; Diebold RB; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Bouska J; Olson A; Marsh KC; Stoll VS; Mamo M; Polakowski J; Campbell TJ; Martin RL; Gintant GA; Penning TD; Li Q; Rosenberg SH; Giranda VL
J Med Chem; 2007 Jun; 50(13):2990-3003. PubMed ID: 17523610
[TBL] [Abstract][Full Text] [Related]
17. Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase.
Cumming JG; McKenzie CL; Bowden SG; Campbell D; Masters DJ; Breed J; Jewsbury PJ
Bioorg Med Chem Lett; 2004 Nov; 14(21):5389-94. PubMed ID: 15454232
[TBL] [Abstract][Full Text] [Related]
18. Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account.
Wu F; Büttner FH; Chen R; Hickey E; Jakes S; Kaplita P; Kashem MA; Kerr S; Kugler S; Paw Z; Prokopowicz A; Shih CK; Snow R; Young E; Cywin CL
Bioorg Med Chem Lett; 2010 Jun; 20(11):3235-9. PubMed ID: 20462760
[TBL] [Abstract][Full Text] [Related]
19. Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension.
Shaw D; Hollingworth G; Soldermann N; Sprague E; Schuler W; Vangrevelinghe E; Duggan N; Thomas M; Kosaka T; Waters N; van Eis MJ
Bioorg Med Chem Lett; 2014 Oct; 24(20):4812-7. PubMed ID: 25248678
[TBL] [Abstract][Full Text] [Related]
20. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
